Pacira BioSciences Inc. (NASDAQ: PCRX) sent a letter to stockholders defending its three board nominees ahead of its June 9, 2026 annual meeting, according to a company statement.

The company is recommending stockholders vote for Christopher Christie, Samit Hirawat and Thomas Wiggans, while opposing three candidates nominated by DOMA Perpetual Capital Management LLC.

Christie, an independent director since September 2019, served as New Jersey's governor from 2010 to 2018 and chaired the President's Commission on Combating Drug Addiction and the Opioid Crisis in 2017. Hirawat, who joined the board in January 2026, previously served as chief medical officer at Bristol Myers Squibb (NYSE: BMY) from June 2019 to October 2025, where he oversaw approval of 13 new molecular entities.

Wiggans brings over 40 years of life sciences experience and served as CEO of four companies with successful exits. He co-founded Dermira in 2010 and led the company as CEO and chairman until its acquisition by Eli Lilly in 2020.

Pacira's board interviewed two of DOMA's three nominees and determined they were underqualified. The third nominee, Eric de Armas, who serves as DOMA's chief financial officer, chief compliance officer and chief operating officer, did not make himself available for an interview despite multiple requests from Pacira.

The company stated that DOMA's nominees lack experience operating within the biopharmaceutical industry and do not have the governance expertise necessary for a publicly traded company. Pacira also noted potential conflicts of interest regarding de Armas given his roles at DOMA.

Following the annual meeting, Pacira's board will comprise nine directors, with eight being independent if the company's nominees are elected. Stockholders of record as of April 22, 2026 are entitled to vote at the meeting.